315 reports of this reaction
3.7% of all REGADENOSON reports
#5 most reported adverse reaction
HEADACHE is the #5 most commonly reported adverse reaction for REGADENOSON, manufactured by Astellas Pharma US, Inc.. There are 315 FDA adverse event reports linking REGADENOSON to HEADACHE. This represents approximately 3.7% of all 8,610 adverse event reports for this drug.
Patients taking REGADENOSON who experience headache should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HEADACHE is moderately reported among REGADENOSON users, representing a notable but not dominant share of adverse events.
In addition to headache, the following adverse reactions have been reported for REGADENOSON:
The following drugs have also been linked to headache in FDA adverse event reports:
HEADACHE has been reported as an adverse event in 315 FDA reports for REGADENOSON. This does not prove causation, but indicates an association observed in post-market surveillance data.
HEADACHE accounts for approximately 3.7% of all adverse event reports for REGADENOSON, making it a notable side effect.
If you experience headache while taking REGADENOSON, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.